Spontaneous regression of tumor-stage cutaneous T-cell lymphoma in a multiple sclerosis patient after discontinuing fingolimod

Abstract

Get full access to this article

View all access options for this article.

References

Papathemeli

Grafe

Hildebrandt

et al . Development of a primary cutaneous CD30(+) anaplastic large-cell T-cell lymphoma during treatment of multiple sclerosis with fingolimod. Mult Scler 2016; 22(14): 1888–1890.

Jawed

Myskowski

Horwitz

et al . Primary cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome):part I. Diagnosis: Clinical and histopathologic features and new molecular and biologic markers. J Am Acad Dermatol 2014; 70(2): 205.e1–205.e16, quiz 221–222.

Vowels

Lessin

Cassin

et al . Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma. J Invest Dermatol 1994; 103: 669–673.

Kappos

O‘Connor

Radue

et al . Long-term effects of fingolimod in multiple sclerosis: The randomized FREEDOMS extension trial. Neurology 2015; 84(15): 1582–1591.

Lorvik

Bogen

Corthay

Fingolimod blocks immunosurveillance of myeloma and B-cell lymphoma resulting in cancer development in mice. Blood 2012; 119(9): 2176–2177.

Cohan

Godwin

Gaedeke

Acute lymphoblastic leukemia in a man treated with fingolimod for relapsing multiple sclerosis. J Investig Med High Impact Case Rep 2015; 3(1): 2324709615575551.

Cohen

Khatri

Barkhof

et al . Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: Results from the extension of the randomised TRANSFORMS study. J Neurol Neurosurg Psychiatry 2016; 87(5): 468–475.